source
- Merck/Kelun ADC sac-TMT cuts death risk by one-third in advanced endometrial cancerA randomized Phase 3 trial showed that the antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT) reduced the risk of death by about one‑third in patients with advanced endometrial cancer. The…
- Genmab’s Rina-S ADC cuts risk of progression and death in Phase 3 ovarian cancer trialGenmab reported results from its Phase 3 RAINFOL-02 trial of the FRα‑directed antibody‑drug conjugate Rina‑S (rinatabart sesutecan) in patients with platinum‑resistant ovarian cancer. In the inten…